Compare INDV & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDV | EWTX |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.3B |
| IPO Year | 2014 | 2021 |
| Metric | INDV | EWTX |
|---|---|---|
| Price | $35.64 | $38.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $49.50 | ★ $52.62 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8100.00 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $1,239,000,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $27.68 | $16.70 |
| 52 Week High | $42.81 | $48.51 |
| Indicator | INDV | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 43.36 |
| Support Level | $32.90 | $37.33 |
| Resistance Level | $35.93 | $41.13 |
| Average True Range (ATR) | 1.41 | 1.83 |
| MACD | 0.12 | 0.18 |
| Stochastic Oscillator | 68.87 | 44.67 |
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.